The Surgeon's Role in Multi-modal Treatment of Gastro-esophageal Tumors

Thursday, March 10, 2022

8:00 AM – 9:30 AM CST

Location:Coronado

Moderator(s)

Evan Glazer, MD, PhD, FACS, FSSO

Assistant Professor of Surgery
University of Tennessee Health Science Center
Memphis, TN, United States

Participants should be aware of the following financial/non-financial relationships:

Evan S. Glazer, MD, PhD, FACS, FSSO: I do not have any relevant financial / non-financial relationships with any proprietary interests.

"Participants will be abe to
1. Identify appropriate candidates for chemoinduction therapy in patients with Siewert type II tumors, as well as complex surgical approaches for large tumors
2. Determine the right time/patient/tumor to add chemoradiation for Siewert type III tumors
3. Understand the role of the surgeon in the evolving era of immunotherapy for esophageal adenocarcinomas"

CME

Presentations:

8:00 AM – 8:02 AM CST

Introductions
8:02 AM – 8:22 AM CST

Induction Chemotherapy in Siewert Type II Cancers
Presenter: Timothy J. Kennedy, MD, MBA – Rutgers Cancer Institute of New Jersey
8:22 AM – 8:27 AM CST

Panel Discussion
8:27 AM – 8:47 AM CST

Chemoradiation for Siewert Type III Cancers
Presenter: Moshim Kukar, MD – Roswell Park Comprehensive Cancer Center
8:47 AM – 8:52 AM CST

Panel Discussion
8:52 AM – 9:12 AM CST

Role of the Surgical Oncologist in the Era of Immunotherapy for Esophageal Cancers
Presenter: Richelle T. Williams, MD, MS – University of Maryland
9:12 AM – 9:15 AM CST

Panel Discussion
9:17 AM – 9:30 AM CST

Q&A